Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Completed · Phase 3

Conditions studied: Hypertension

In brief

This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses. The low dose ranges from 6.25 mg to 25 mg of aliskiren, the mid dose ranges from 37.5 mg to 150 mg of aliskiren and the high dose ranges from 150 mg to 600 mg of aliskiren. This study is being conducted to support monotherapy registration of aliskiren for the treatment of hypertension in children 6-17 years of age.

Key facts

Study ID

NCT01150357

Run by

Novartis Pharmaceuticals

People needed

267

Starts

2010-06-01

Expected to finish

2014-08-01

Last updated by the study team

2015-10-15

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented diagnosis of hypertension as defined in the NHLBI 4th Report, 2004
• msSBP (mean of 3 measurements) must be ≥ 95th percentile for age, gender and height, at Visit 2 (randomization) measurement as defined by the NHLBI 4th Report, 2004

You may not qualify if…

• Patient receiving immunosuppressant medication (e.g. cyclosporine, MMF, etc) other than oral/topical steroids, for any medical condition
• Current diagnosis of heart failure (NYHA Class II-IV) or history of cardiomyopathy or obstructive valvular disease
• msSBP ≥ 25% above the 95th percentile
• Second or third degree heart block without a pacemaker
• AST/SGOT or ALT/SGPT >3 times the upper limit of the reference range
• Total bilirubin > 2 times the upper limit of the reference range
• Creatinine clearance < 30 mL/min/1.73m² (calculated using Modified Schwartz formula to estimate glomerular filtration rate [GFR]), based on the serum creatinine concentration obtained at the screening visit)
• WBC count < 3000/mm³
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Birmingham, Alabama, United States
• Novartis Investigative Site — Little Rock, Arkansas, United States
• Novartis Investigative Site — Los Angeles, California, United States
• Novartis Investigative Site — San Diego, California, United States
• Novartis Investigative Site — Pensacola, Florida, United States
• Novartis Investigative Site — Atlanta, Georgia, United States
• Novartis Investigative Site — Dalton, Georgia, United States
• Novartis Investigative Site — Lewiston, Idaho, United States
• Novartis Investigative Site — Park Ridge, Illinois, United States
• Novartis Investigative Site — Louisville, Kentucky, United States
• Novartis Investigative Site — Hattiesburg, Mississippi, United States
• Novartis Investigative Site — Jackson, Mississippi, United States
• Novartis Investigative Site — Hackensack, New Jersey, United States
• Novartis Investigative Site — New York, New York, United States
• Novartis Investigative Site — Columbus, Ohio, United States
• Novartis Investigative Site — Toledo, Ohio, United States
• Novartis Investigative Site — Portland, Oregon, United States
• Novartis Investigative Site — Portland, Oregon, United States
• Novartis Investigative Site — Pittsburgh, Pennsylvania, United States
• Novartis Investigative Site — Charleston, South Carolina, United States
• Novartis Investigative Site — Amarillo, Texas, United States
• Novartis Investigative Site — Seattle, Washington, United States
• Novartis Investigative Site — Charleston, West Virginia, United States
• Novartis Investigative Site — Brussels, Belgium
• Novartis Investigative Site — Edegem, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.